Skip to main content
main-content

Rheumatology

Latest articles

07-11-2018 | Rheumatology | News | Article

Low-dose radiation therapy not helpful in knee OA

Low-dose radiation therapy has no significant effect on symptoms or inflammatory markers when used in the treatment of knee osteoarthritis, study findings indicate.

Source:

Ann Rhem Dis 2018; doi:10.1136/annrheumdis-2018-214104

05-11-2018 | Rheumatology | News | Article

Elevated autoimmune thyroid disease risk in RA patients declines over time

Study findings suggest that patients with rheumatoid arthritis have an increased risk for autoimmune thyroid disease relative to the general population in the period leading up to arthritis diagnosis, but the risk reduces after this time.

Source:

JAMA Netw Open 2018; 1: e183567

02-11-2018 | Rheumatology | News | Article

Gout patients may benefit from nurse-led care

Nurse-led care involving patient education and engagement increases the likelihood of achieving target serum urate levels among individuals with gout, findings from a UK randomized controlled trial suggest.

Source:

Lancet 2018; 392: 1379–1381, 1403–1412

01-11-2018 | Rheumatology | News | Article

ACR/ARHP 2018

Tocilizumab-treated RA patients with LDA ‘should be considered’ for glucocorticoid tapering

Findings from a randomized controlled trial suggest that glucocorticoid tapering is a feasible strategy for rheumatoid arthritis patients who achieve low disease activity or remission during treatment with tocilizumab and long-term glucocorticoids.

Source:

ACR/ARHP Annual Meeting; Chicago, Illinois, USA: 19–24 October 2018

01-11-2018 | Rheumatology | News | Article

Imaging tests show potential for early diagnosis of GCA

Findings from two studies presented at the 2018 ACR/ARHP Annual Meeting in Chicago, Illinois, USA, suggest that noninvasive imaging tests may have a role in the detection of giant cell arteritis.

Source:

ACR/ARHP Annual Meeting; Chicago, Illinois, USA: 19–24 October 2018

31-10-2018 | Rheumatology | News | Article

Post-hoc analysis supports further investigation of ustekinumab in PsA-associated spondylitis

Treatment with ustekinumab may be beneficial for some patients with psoriatic arthritis and spondylitis, suggests a post-hoc subgroup analysis of the PSUMMIT 1 and 2 trials.

Source:

ACR/ARHP Annual Meeting; Chicago, Illinois, USA: 19–24 October 2018

29-10-2018 | Rheumatology | News | Article

Peficitinib may be a promising treatment option for RA

Findings from two phase III trials presented at the 2018 ACR/ARHP Annual Meeting in Chicago, Illinois, USA, demonstrate that treatment with the JAK inhibitor peficitinib may be beneficial for patients with rheumatoid arthritis.

Source:

ACR/ARHP Annual Meeting; Chicago, Illinois, USA: 19–24 October 2018

26-10-2018 | Rheumatology | News | Article

ACR/ARHP 2018

Further evidence for the benefits of ixekizumab in ankylosing spondylitis

Findings from the COAST-W trial provide support for the IL-17A inhibitor ixekizumab as a treatment option for patients with ankylosing spondylitis and a previous inadequate response or intolerance to TNF inhibitor treatment.

Source:

ACR/ARHP Annual Meeting; Chicago, Illinois, USA: 19–24 October 2018

26-10-2018 | Rheumatology | News | Article

Editor's pick

Further investigation of filgotinib warranted in ankylosing spondylitis patients

Findings from the phase II TORTUGA trial suggest that treatment with the JAK1 inhibitor filgotinib may be beneficial for patients with ankylosing spondylitis who have not responded to treatment with nonsteroidal anti-inflammatory drugs.

Source:

Lancet 2018; doi:10.1016/S0140-6736(18)32463-2
Lancet 2018; doi:10.1016/S0140-6736(18)32600-X

25-10-2018 | Rheumatology | News | Article

ACR/ARHP 2018

RA patients experience enhanced immune response with high-dose influenza vaccine

Findings from a randomised controlled trial suggest that rheumatoid arthritis patients who are given a high-dose influenza vaccine experience a stronger immune response than those given a standard dose.

Source:

ACR/ARHP Annual Meeting; Chicago, Illinois, USA: 19–24 October 2018

25-10-2018 | Rheumatology | News | Article

ACR/ARHP 2018

Ultrasound shows potential for early diagnosis of large vessel giant cell arteritis

Vascular ultrasound could be a contender as a first-line imaging test for diagnosing large vessel giant cell arteritis, suggests research.

Source:

ACR/ARHP Annual Meeting; Chicago, Illinois, USA: 19–24 October 2018

24-10-2018 | Rheumatology | News | Article

ACR/ARHP 2018 news in brief

Genetic risk scores may aid ankylosing spondylitis detection

Researchers have developed two polygenic risk scores to identify individuals at high risk for ankylosing spondylitis.

24-10-2018 | Rheumatology | News | Article

ACR/ARHP 2018

Two-year data support denosumab use in patients with glucocorticoid-induced osteoporosis

Greater increases in bone mineral density seen with denosumab versus risedronate in glucocorticoid-treated patients with osteoporosis are sustained through 24 months, indicate phase III data.

Source:

ACR/ARHP Annual Meeting; Chicago, Illinois, USA: 19–24 October 2018

24-10-2018 | Rheumatology | News | Article

ACR/ARHP 2018

Etanercept outperforms methotrexate for PsA

Etanercept has greater efficacy than methotrexate for the treatment of psoriatic arthritis, suggest phase III trial results presented at the 2018 ACR/ARHP Annual Meeting in Chicago, Illinois, USA.

Source:

ACR/ARHP Annual Meeting; Chicago, Illinois, USA: 19–24 October 2018

24-10-2018 | Rheumatology | News | Article

ACR/ARHP 2018

Similar pain benefits with surgery and physical therapy for osteoarthritis meniscal tear

Patients with osteoarthritis who have degenerative meniscal tear experience pain relief with either physical therapy or arthroscopic partial meniscectomy, show 5-year MeTeOR data.

Source:

ACR/ARHP Annual Meeting; Chicago, Illinois, USA: 19–24 October 2018

23-10-2018 | Rheumatology | News | Article

ACR/ARHP 2018

Filgotinib shows promise in psoriatic arthritis treatment

The selective janus kinase 1 inhibitor filgotinib has shown efficacy in patients with psoriatic arthritis with no new safety signals, show phase II data from the EQUATOR study.

Source:

Lancet 2018; doi:10.1016/S0140-6736(18)32483-8
ACR/ARHP Annual Meeting; Chicago, Illinois, USA: 19–24 October 2018

23-10-2018 | Rheumatology | News | Article

Editor's pick

COAST-V results support ixekizumab for the treatment of ankylosing spondylitis

Phase III trial results indicate that ixekizumab may be a promising treatment option for biologic-naïve patients with ankylosing spondylitis and an inadequate response or intolerance to nonsteroidal anti-inflammatory drugs.

Source:

Lancet 2018; doi:10.1016/S0140-6736(18)31946-9
Lancet 2018; doi:10.1016/S0140-6736(18)32340-7
ACR/ARHP Annual Meeting; Chicago, Illinois, USA: 19–24 October 2018

23-10-2018 | Rheumatology | News | Article

Interstitial lung disease risk linked to rheumatoid arthritis disease severity

Moderate-to-high rheumatoid arthritis disease activity is associated with a twofold increased risk for associated interstitial lung disease, compared with remission or low disease activity, study findings show.

Source:

ACR/ARHP Annual Meeting; Chicago, Illinois, USA: 19–24 October 2018

23-10-2018 | Rheumatology | News | Article

ACR/ARHP 2018

Very early intervention with secukinumab may be a feasible approach in PsA

Findings from a small study suggest that treatment with the interleukin-17A inhibitor secukinumab may be a promising strategy to reduce inflammation in psoriasis patients with subclinical peripheral joint involvement.

Source:

ACR/ARHP Annual Meeting; Chicago, Illinois, USA: 19–24 October 2018 

23-10-2018 | Rheumatology | News | Article

ACR/ARHP 2018

Rheumatic adverse events described in patients treated with immune checkpoint inhibitors

Researchers have characterized rheumatic immune-related adverse events that occur in patients with cancer who are undergoing treatment with immune checkpoint inhibitors.

Source:

Arthritis Rheumatol 2018; doi:10.1002/art.40745

image credits